万落生，博士
E-mail:wanluosheng@hust.edu.cn; TeL：13797014209
教育及工作经历
2017.11-至今，华中科技大学，副教授，硕士生导师；
2016.09-2017.11，华中科技大学，讲师，硕士生导师；
2013.07-2016.06，中国科学院昆明植物研究所，药学博士后；
2008.09-2013.06，华中科技大学，药理学博士；
2004.09-2008.06，华中科技大学，生物药学学士.
研究方向
中药活性成分、中药复方创新研制
科研项目与专利
1.以Kv1.3离子通道为靶点的大戟属植物抗银屑病药效物质基础研究,国家自然科学基金面上项目，59万元，主持人；
2.滇产三种黄杨属植物抗肿瘤作用及资源品质评价，国家自然科学基金青年项目，23万元，主持人；
3.二萜类化合物及制备方法和应用、二萜类化合物药学上可接受的衍生物、药物组合物及应用，CN202111202584.7.
代表性论文(*corresponding author, #first author)
1. Hu ZF#, Su JC#, Sun X#, Xia RF, Wu JL, Fu XN, Zhang BZ*, Chen JC*,Wan LS*. Brujavanoids A-U, structurally diverse apotirucallane-type triterpenoids fromBrucea javanicaand their anti-inflammatory effects.Bioorg. Chem.2022, 127: 106012.(JCR Q1, IF: 5.307)
2. Xiang ZN#, Tong QL#, Su JC#, Hu ZF#, Zhao N, Xia RF, Wu JL, Chen C, Chen JC*,Wan LS*. Diterpenoids with Rearranged 9(10→11)-abeo-10,12-Cyclojatrophane Skeleton and the First (15S)-Jatrophane fromEuphorbia helioscopia: Structural Elucidation, Biomimetic Conversion, and Their Immunosuppressive Effects.Org. Lett.2022, 24: 697-701.(JCR Q1, IF: 6.072)
3. Zhou CG, Xiang ZN, Zhao N, Sun X, Hu ZF, Wu JL, Xia RF, Chen C, Su JC*, Chen JC*,Wan LS*. Jatrophane Diterpenoids with Kv1.3 Ion Channel Inhibitory Effects fromEuphorbia helioscopia.J. Nat. Prod.2022, 85: 815-827.(JCR Q1, IF: 4.803)
4. Xie H, Tong Q, Xiang Z, Zhou C,Wan LS*, Chen J*. Demethylbellidifolin, a potential aldose reductase inhibitor ameliorates diabetic nephropathy by regulating the polyol pathway.Phytomedicine Plus2022, 2: 100152.
5. Pan J#, Su JC#, Liu YH, Deng B, Hu ZF, Wu JL, Xia RF, Chen C, He Q, Chen JC*,Wan LS*. Stelleranoids A-M, guaiane-type sesquiterpenoids based on [5,7] bicyclic system fromStellera chamaejasmeand their cytotoxic activity.Bioorg. Chem.2021, 115: 105251.(JCR Q1, IF: 5.307)
6. Xiang ZN, Su JC, Liu YH, Deng B, Zhao N, Pan J, Hu ZF, Chen FH, Cheng BY, Chen JC*,Wan LS*. Structurally diverse alkaloids fromBuxus sempervirenswith cardioprotective activity.Bioorg. Chem.2021, 109: 104753.(JCR Q1, IF: 5.307)
7. Xiang Z, Xie H, Tong Q, Pan J,Wan L*, Fang J*, Chen J*. Revealing hypoglycemic and hypolipidemic mechanism ofXiaokeyinshuiextract combination on streptozotocin-induced diabetic mice in high sucrose/high fat diet by metabolomics and lipidomics.Biomed. Pharmacother.2021, 135: 111219.(JCR Q1, IF: 7.419)
8. Liu YH, Xiang ZN, Chen C,Wan LS*, Chen JC*. Hypolipidemic and Hepatoprotective Effects of Polysaccharides Extracted fromLiriope spicataVar.Proliferain C57BL/6J Mice with High-Fat Diet-Induced Hyperlipidemia.Evid. Based. Complement. Alternat. Med.2020, 2020: 8013189.(JCR Q3, IF: 2.650)
9. Zhou J, Pan J, Xiang Z, Wang Q, Tong Q, Fang J,Wan L*, Chen J*. Data on the optimization of the formula ofXiaokeyinshuiextract combination treating diabetes mellitus using uniform experimental design in mice.Data in Brief2020, 32: 106134.
10. Zhou J, Pan J, Xiang Z, Wang Q, Tong Q, Fang J,Wan L*, Chen J*. Xiaokeyinshui extract combination, a berberine-containing agent, exerts anti-diabetic and renal protective effects on rats in multi-target mechanisms.J. Ethnopharmacol.2020, 262: 113098.(JCR Q1, IF: 5.195)
11. Wang YL, Xiang ZN, Yuan Y, Zhou JW, Tian LY, Chen JC*,Wan LS*. Triterpenoid alkaloids fromBuxus rugulosaand their cytotoxic activities.Phytochem. Lett.2020, 36: 86-90.(JCR Q3, IF: 1.873)
12. Yuan Y, Wang QY, Zhang J, Nie J, Zhou CG, Yi WQ,Wan LS*, Chen JC*. A new bile acid from the traditional chinese medicineshedan.J. Asian Nat. Prod. Res.2019, PMID: 31535572.(JCR Q3, IF: 1.610)
13. Zhou J, Wang Q, Xiang Z, Tong Q, Pan J,Wan L*, Chen J*. Network Pharmacology Analysis of Traditional Chinese Medicine Formula Xiao Ke Yin Shui Treating Type 2 Diabetes Mellitus.Evid. Based. Complement. Alternat. Med.2019, 2019: 4202563.(JCR Q3, IF: 2.650)
14. Wang Q, Zhou J, Xiang Z, Tong Q, Pan J,Wan L*, Chen J*. Anti-diabetic and renoprotective effects of Cassiae Semen extract in the streptozotocin-induced diabetic rats.J. Ethnopharmacol.2019, 2019: 111904.(JCR Q1, IF: 5.195)
15. Xiang ZN, Yi WQ, Wang YL, Shao LD, Zhang CQ, Yuan Y, Pan J,Wan LS*, Chen JC*. Buxaustroines A-N, a Series of 17(13→18)abeo-Cycloartenol Triterpenoidal Alkaloids fromBuxus austro-yunnanensisand Their Cardioprotective Activities.J. Nat. Prod.2019, 82: 3111-3120.(JCR Q1, IF: 4.803)
16. Wan LS#, Nian Y#, Peng XR, Shao LD, Li XN, Yang J, Zhou M*, and Qiu MH*, Pepluanols C–D, Two Diterpenoids with Two Skeletons fromEuphorbia peplus.Org. Lett.2018, 20: 3074-3120.(JCR Q1, IF: 6.072)
17. Gong Y, Zhang J, Gao F, Zhou J, Xiang Z, Zhou C,Wan L*, Chen J*. Structure features and in vitro hypoglycemic activities of polysaccharides from different species ofMaidong.Carbohydr. Polym.2017, 173: 215-222.(JCR Q1, IF: 10.723)
18. Bai ST, Zhu GL, Peng XR, Dong JR, Yu MY, Chen JC,Wan LS*, Qiu MHu*. Cytotoxicity of Triterpenoid Alkaloids fromBuxus microphyllaagainst Human Tumor Cell Lines.Molecules2016, 21: 1125.(JCR Q2, IF: 4.927)
19. Wan LS#, Nian Y#, Ye CJ#, Shao LD, Peng XR, Geng CA, Zuo ZL, Li XN, Yang J, Zhou M*, Qiu MH*. Three Minor Diterpenoids with Three Carbon Skeletons fromEuphorbia peplus.Org. Lett.2016, 18: 2166-2169.(JCR Q1, IF: 6.072)
20. Wan LS, Shao LD, Fu L, Xu J, Zhu GL, Peng XR, Li XN, Li Yan, Qiu MH*. One-Step Semisynthesis of a Segetane Diterpenoid from a Jatrophane Precursor via a Diels-Alder Reaction.Org. Lett.2016, 18: 496-499.(JCR Q1, IF: 6.072)
21. Wan LS, Chu R, Peng XR, Zhu GL, Yu MY, Li L, Zhou L, Lu SY, Dong JR, Zhang ZR, Li Y, Qiu MH*. Pepluane and Paraliane Diterpenoids fromEuphorbia pepluswith Potential Anti-inflammatory Activity.J. Nat. Prod.2016, 79: 1628-1634.(JCR Q1, IF: 4.803)
22. Wan LS, Min QX, Wang YL, Yue YD, Chen JC*. Xanthone Glycoside Constituents ofSwertia kouitchensiswith α-Glucosidase Inhibitory Activity.J. Nat Prod.2013, 76: 1248-1253.(JCR Q1, IF: 4.803)
23. Wan LS, Liu TT, Lin XJ, Min QX, Chen JC*, Two New Chiratane-Type Triterpenoids fromSwertia kouitchensis.Molecules2013, 18: 8518-8523.(JCR Q2, IF: 4.927)
24. Wan LS, Chen CP, Xiao ZQ, Wang YL, Min QX, Yue Y, Chen J*. In vitro and in vivo anti-diabetic activity ofSwertia kouitchensisextract.J. Ethnopharmacol.2013, 147: 622-630.(JCR Q1, IF: 5.195)
